$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000160062023000012 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$41.49M	$34.41M
YoY Change	47.19%	59.12%
Cost Of Revenue	$1.563M	$421.0K
YoY Change	-2.25%	64.45%
Gross Profit	$39.93M	$33.99M
YoY Change	50.16%	59.05%
Gross Profit Margin	96.23%	98.78%
Selling, General & Admin	$47.08M	$50.12M
YoY Change	-8.64%	10.9%
% of Gross Profit	117.91%	147.48%
Research & Development	$12.65M	$13.16M
YoY Change	9.76%	4.26%
% of Gross Profit	31.68%	38.71%
Depreciation & Amortization	$620.0K	$623.0K
YoY Change	-37.44%	-9.32%
% of Gross Profit	1.55%	1.83%
Operating Expenses	$56.10M	$13.16M
YoY Change	386.78%	4.26%
Operating Profit	-$16.17M	-$29.58M
YoY Change	-55.07%	-21.9%
Interest Expense	$4.036M	$3.814M
YoY Change	735.61%	1355.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.13M	-$25.77M
YoY Change	-65.83%	-31.5%
Income Tax	-$642.0K	$436.0K
% Of Pretax Income
Net Earnings	-$11.49M	-$26.21M
YoY Change	-67.64%	-30.36%
Net Earnings / Revenue	-27.7%	-76.16%
Basic Earnings Per Share	-$0.08	-$0.18
Diluted Earnings Per Share	-$0.08	-$0.18
COMMON SHARES
Basic Shares Outstanding	143.0M shares	142.6M shares
Diluted Shares Outstanding	142.8M shares	142.6M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$350.7M	$361.5M
YoY Change	-10.47%	-13.66%
Cash & Equivalents	$81.71M	$88.33M
Short-Term Investments	$269.0M	$272.5M
Other Short-Term Assets	$12.54M	$1.227M
YoY Change	1052.57%	-69.06%
Inventory	$33.16M	$31.75M
Prepaid Expenses	$11.33M	$10.10M
Receivables	$19.50M	$19.05M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$415.9M	$423.6M
YoY Change	-8.23%	-11.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$125.8M	$3.842M
YoY Change	2907.22%	-11.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.518M	$13.36M
YoY Change	-87.71%	12.83%
Total Long-Term Assets	$133.0M	$28.11M
YoY Change	359.31%	-4.0%
TOTAL ASSETS
Total Short-Term Assets	$415.9M	$423.6M
Total Long-Term Assets	$133.0M	$28.11M
Total Assets	$548.9M	$451.8M
YoY Change	13.84%	-10.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.808M	$3.680M
YoY Change	485.63%	12.64%
Accrued Expenses	$37.38M	$32.17M
YoY Change	14.97%	6.99%
Deferred Revenue	$3.228M	$3.157M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.02M
YoY Change
Total Short-Term Liabilities	$61.66M	$42.05M
YoY Change	78.08%	24.26%
LONG-TERM LIABILITIES
Long-Term Debt	$79.42M	$0.00
YoY Change
Other Long-Term Liabilities	$15.53M	$12.30M
YoY Change	-4.75%	-29.31%
Total Long-Term Liabilities	$94.95M	$12.30M
YoY Change	482.5%	-29.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$61.66M	$42.05M
Total Long-Term Liabilities	$94.95M	$12.30M
Total Liabilities	$156.6M	$61.35M
YoY Change	168.26%	4.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$902.0M	-$890.5M
YoY Change	8.77%	12.19%
Common Stock	$98.83M	$88.89M
YoY Change	33.55%	37.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$392.3M	$390.4M
YoY Change
Total Liabilities & Shareholders Equity	$548.9M	$451.8M
YoY Change	13.84%	-10.88%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$11.49M	-$26.21M
YoY Change	-67.64%	-30.36%
Depreciation, Depletion And Amortization	$620.0K	$623.0K
YoY Change	-37.44%	-9.32%
Cash From Operating Activities	-$2.826M	-$31.67M
YoY Change	-89.86%	-32.25%
INVESTING ACTIVITIES
Capital Expenditures	$227.0K	$509.0K
YoY Change	-682.05%	-744.3%
Acquisitions
YoY Change
Other Investing Activities	-$5.381M	$25.37M
YoY Change	-111.78%	-147.92%
Cash From Investing Activities	-$5.608M	$24.86M
YoY Change	-112.29%	-146.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.140M	$1.639M
YoY Change	-14.93%	304.69%
NET CHANGE
Cash From Operating Activities	-2.826M	-$31.67M
Cash From Investing Activities	-5.608M	$24.86M
Cash From Financing Activities	1.140M	$1.639M
Net Change In Cash	-7.294M	-$5.171M
YoY Change	-138.21%	-94.8%
FREE CASH FLOW
Cash From Operating Activities	-$2.826M	-$31.67M
Capital Expenditures	$227.0K	$509.0K
Free Cash Flow	-$3.053M	-$32.18M
YoY Change	-89.03%	-31.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36421
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	#140, 14315 - 118 Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Edmonton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	AB
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	T5L 4S6
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1231763
CY2023Q1	dei	City Area Code CityAreaCode	(250)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	744-2487
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143034009	shares
CY2023Q1	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2023Q1	dei	Trading Symbol TradingSymbol	AUPH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89001000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94172000	usd
CY2023Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	272533000	usd
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	295218000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	19046000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13483000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	31745000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24752000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10096000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13580000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1227000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1334000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	423648000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	442539000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13357000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13339000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3842000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3650000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6101000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6425000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4813000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4907000	usd
CY2023Q1	us-gaap	Assets Assets	451761000	usd
CY2022Q4	us-gaap	Assets Assets	470860000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	35965000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39990000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3157000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3148000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1979000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2033000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	945000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	936000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	42046000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46107000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12321000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12166000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6986000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7152000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	61353000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	65425000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143029000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143029000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142268000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142268000	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1193019000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1185309000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	88885000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	85489000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-988000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1061000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-890508000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-864302000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	390408000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	405435000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	451761000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	470860000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34409000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21625000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	421000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	256000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50124000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45197000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13158000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12620000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-290000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1434000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	63993000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	59507000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29584000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37882000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3814000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	262000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25770000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37620000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	436000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26206000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	73000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-766000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26133000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38396000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142641000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142641000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141675000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141675000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	405435000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1639000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9467000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	73000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26206000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	390408000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	405000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7023000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-766000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	448123000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26206000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	623000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	687000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	151000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2611000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-140000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9467000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7023000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-217000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1374000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5559000	usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4986000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6993000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6940000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3588000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-307000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	17000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4117000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6704000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-156000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-168000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31670000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46746000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	142397000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	163504000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	167766000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	110566000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	347000	usd
CY2022Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	79000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	162000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24860000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53017000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1639000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	405000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1639000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	405000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5171000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-99358000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94172000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89001000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132542000	usd
CY2023Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1595000	usd
CY2022Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	13000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	263000	usd
CY2022Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	281000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88327000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131636000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	674000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	906000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89001000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132542000	usd
CY2021Q3	auph	Number Of Additional Novel Assets NumberOfAdditionalNovelAssets	2	assets
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	auph	Cash Cash Equivalents And Debt Securities Current CashCashEquivalentsAndDebtSecuritiesCurrent	361500000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	700000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	100000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product in the Otsuka Territories. Revenues from the two main customers in the U.S. accounted in total of approximately 99% for the three months ended March 31, 2023 and March 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to our customers or receivables.</span></div>
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	19000000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13500000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	361534000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	389390000	usd
CY2023Q1	auph	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Short Term Investments CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments	361500000	usd
CY2022Q4	auph	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Short Term Investments CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments	389400000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	272500000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	295200000	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	361716000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	1000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	183000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	361534000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	389646000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	256000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	389390000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	600000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	1100000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	100000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3900000	usd
CY2023Q1	auph	Prepaid Assets Current PrepaidAssetsCurrent	6043000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1115000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	29522000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	21059000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1108000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1476000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	31745000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	24752000	usd
CY2022Q4	auph	Prepaid Assets Current PrepaidAssetsCurrent	5451000	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	3308000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	6330000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	745000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1799000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10096000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13580000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19723000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13622000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6101000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19568000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13143000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6425000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5290000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5105000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1448000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1455000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3842000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3650000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	usd
CY2021Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21000000	chf
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0525
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	718000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1113000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1141000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1169000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1198000	usd
CY2023Q1	auph	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4532000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9871000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1940000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7931000	usd
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	usd
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10500000	chf
CY2023Q1	auph	Lessee Operating Lease Lease Not Yet Commenced Payments Prior To Commencement Of Lease LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease	1000000	usd
CY2023Q1	auph	Lessee Operating Lease Lease Not Yet Commenced Liability To Be Paid LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid	100000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11721000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20214000	usd
CY2023Q1	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	10689000	usd
CY2022Q4	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	8620000	usd
CY2023Q1	auph	Accrued Research Current AccruedResearchCurrent	5621000	usd
CY2022Q4	auph	Accrued Research Current AccruedResearchCurrent	5350000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3680000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3087000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3194000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2094000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1060000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	625000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	35965000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39990000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12300000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12200000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26206000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142641000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142641000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141675000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141675000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20582000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16601000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.71
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.70
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0408
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0173
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.127
CY2022Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.116
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.44
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.02
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13295000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.09
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.84
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	319000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.09
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	530000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12678000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.11
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9467000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7023000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	50900000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	436000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd

Files In Submission

Name	View Source	Status
0001600620-23-000012-index-headers.html	Edgar Link	pending
0001600620-23-000012-index.html	Edgar Link	pending
0001600620-23-000012.txt	Edgar Link	pending
0001600620-23-000012-xbrl.zip	Edgar Link	pending
auph-20230331.htm	Edgar Link	pending
auph-20230331.xsd	Edgar Link	pending
auph-2023q1exx311.htm	Edgar Link	pending
auph-2023q1exx312.htm	Edgar Link	pending
auph-20230331_cal.xml	Edgar Link	unprocessable
auph-20230331_def.xml	Edgar Link	unprocessable
auph-20230331_pre.xml	Edgar Link	unprocessable
auph-20230331_lab.xml	Edgar Link	unprocessable
auph-20230331_htm.xml	Edgar Link	completed
auph-2023q1exx321.htm	Edgar Link	pending
auph-2023q1exx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2023 Q2 Form 10-Q Financial Statement

#000160062023000012 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2023 Q2 Form 10-Q Financial Statement

#000160062023000012 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph